Literature DB >> 17163303

Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis.

Enzo Ierardi1, Nicola Della Valle, Maurizio Cosimo Nacchiero, Vincenzo De Francesco, Giuseppe Stoppino, Carmine Panella.   

Abstract

We report the case of a patient with refractory ulcerative colitis who developed cholestatic acute liver damage after a single infusion of infliximab. Unusual aspects of this case were the early onset (after the first administration) of liver damage and the absence of antinuclear antibodies, alcohol intake, hepatotoxic drugs and all known viral and metabolic causes of hepatic injury. Moreover, no serological or morphological findings of primary sclerosing cholangitis were observed. The patient's liver damage resolved spontaneously within 6 weeks. Although a direct relationship between administration of infliximab and onset of acute liver damage could not be definitely established, our case suggests that infliximab may induce direct liver damage, the course of which is similar to acute cholestatic hepatitis and resolves following withdrawal of the drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17163303     DOI: 10.2165/00044011-200626110-00008

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  11 in total

1.  Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al.

Authors:  G Saleem; S C Li; B R MacPherson; S M Cooper
Journal:  Arthritis Rheum       Date:  2001-08

2.  Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis.

Authors:  V Germano; A Picchianti Diamanti; G Baccano; E Natale; A Onetti Muda; R Priori; G Valesini
Journal:  Ann Rheum Dis       Date:  2005-10       Impact factor: 19.103

Review 3.  [Criteria of imputation of acute hepatitis to a drug. Results of consensus meetings].

Authors:  G Danan; C Bénichou; B Begaud; M Biour; P Couzigou; J C Evreux; G Lagier; P Berthelot; J P Benhamou
Journal:  Gastroenterol Clin Biol       Date:  1987 Aug-Sep

Review 4.  [Gastrointestinal side effects in the therapy of rheumatologic diseases].

Authors:  U Schiemann; H Kellner
Journal:  Z Gastroenterol       Date:  2002-11       Impact factor: 2.000

5.  Cytokine profiles during infliximab monotherapy in psoriatic arthritis.

Authors:  A Mastroianni; E Minutilli; A Mussi; V Bordignon; E Trento; G D'Agosto; P Cordiali-Fei; E Berardesca
Journal:  Br J Dermatol       Date:  2005-09       Impact factor: 9.302

Review 6.  Pharmacokinetic considerations in the treatment of inflammatory bowel disease.

Authors:  M Schwab; U Klotz
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.

Authors:  M Feletar; J E Brockbank; C T Schentag; V Lapp; D D Gladman
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

8.  Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab.

Authors:  Angel M García Aparicio; José Rey Rey; Azucena Hernández Sanz; Juana Sampedro Alvarez
Journal:  Clin Rheumatol       Date:  2006-07-07       Impact factor: 2.980

9.  Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.

Authors:  M Esteve; C Saro; F González-Huix; F Suarez; M Forné; J M Viver
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

10.  Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.

Authors:  Stephen J Jarrett; Gaye Cunnane; Philip G Conaghan; Sarah J Bingham; Maya H Buch; Mark A Quinn; Paul Emery
Journal:  J Rheumatol       Date:  2003-10       Impact factor: 4.666

View more
  14 in total

1.  Infliximab exerts no direct hepatotoxic effect on HepG2 cells in vitro.

Authors:  Hilbert S de Vries; Tineke de Heij; Henie M J Roelofs; Rene H M te Morsche; Wilbert H M Peters; Dirk J de Jong
Journal:  Dig Dis Sci       Date:  2012-04-26       Impact factor: 3.199

2.  A practical approach to monitoring patients on biological agents for the treatment of psoriasis.

Authors:  Jason J Emer; Amylynne Frankel; Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

Review 3.  Infliximab-related hepatitis: a case study and literature review.

Authors:  Francisco Colina; Aída Molero; Begoña Casís; Pilar Martínez-Montiel
Journal:  Dig Dis Sci       Date:  2013-05-05       Impact factor: 3.199

Review 4.  Anti-tumour necrosis factor agent and liver injury: literature review, recommendations for management.

Authors:  Roberta Elisa Rossi; Ioanna Parisi; Edward John Despott; Andrew Kenneth Burroughs; James O'Beirne; Dario Conte; Mark Ian Hamilton; Charles Daniel Murray
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

Review 5.  Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

Authors:  Marwan Ghabril; Herbert L Bonkovsky; Clarissa Kum; Tim Davern; Paul H Hayashi; David E Kleiner; Jose Serrano; Jim Rochon; Robert J Fontana; Maurizio Bonacini
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

Review 6.  Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Authors:  Robert Hirten; Keith Sultan; Ashby Thomas; David E Bernstein
Journal:  World J Hepatol       Date:  2015-11-28

Review 7.  Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review.

Authors:  Maurizio Pompili; Marco Biolato; Luca Miele; Antonio Grieco
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

Review 8.  Infliximab-related hepatitis: discussion of a case and review of the literature.

Authors:  Stefano Mancini; Elisa Amorotti; Sarah Vecchio; Maurizio Ponz de Leon; Luca Roncucci
Journal:  Intern Emerg Med       Date:  2010-01-27       Impact factor: 3.397

9.  Eculizumab hepatotoxicity in pediatric aHUS.

Authors:  Wesley Hayes; Sibylle Tschumi; Simon C Ling; Janusz Feber; Michael Kirschfink; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2014-11-22       Impact factor: 3.651

10.  Liver Injury Secondary to Anti-TNF-Alpha Therapy in Inflammatory Bowel Disease: A Case Series and Review of the Literature.

Authors:  Ravish Parekh; Nirmal Kaur
Journal:  Case Rep Gastrointest Med       Date:  2014-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.